135 related articles for article (PubMed ID: 2333780)
1. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
Thiebaud D; Jaeger P; Burckhardt P
J Bone Miner Res; 1990 Mar; 5(3):221-6. PubMed ID: 2333780
[TBL] [Abstract][Full Text] [Related]
2. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
3. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
Thiébaud D; Jacquet AF; Burckhardt P
Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
[TBL] [Abstract][Full Text] [Related]
4. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
[TBL] [Abstract][Full Text] [Related]
5. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
Bone; 1986; 7(4):247-53. PubMed ID: 3768203
[TBL] [Abstract][Full Text] [Related]
6. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Coleman RE; Rubens RD
Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
[TBL] [Abstract][Full Text] [Related]
7. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Body JJ; Louviaux I; Dumon JC
Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
[TBL] [Abstract][Full Text] [Related]
8. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
9. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
[TBL] [Abstract][Full Text] [Related]
10. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1988 Jan; 118(3):77-81. PubMed ID: 3344411
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia.
Buchs B; Rizzoli R; Bonjour JP
Bone; 1991; 12(1):47-56. PubMed ID: 2054236
[TBL] [Abstract][Full Text] [Related]
14. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
15. No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
Hené RJ; Visser WJ; Duursma SA; Raymakers JA; de bos Kuil RJ; Dorhout Mees EJ
Bone; 1990; 11(1):15-20. PubMed ID: 2331426
[TBL] [Abstract][Full Text] [Related]
16. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Body JJ; Borkowski A; Cleeren A; Bijvoet OL
J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
[TBL] [Abstract][Full Text] [Related]
17. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
[TBL] [Abstract][Full Text] [Related]
18. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Yates AJ; Murray RM; Jerums GJ; Martin TJ
Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
[TBL] [Abstract][Full Text] [Related]
19. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
20. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
